EIM
LGND icon

Essex Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Essex Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Sell
58,460
-1,560
-3% -$309K 1.85% 5
2025
Q4 		$11.3M Sell
60,020
-1,122
-2% -$216K 1.73% 5
2025
Q3 		$10.8M Buy
61,142
+332
+0.5% +$49.4K 1.66% 8
2025
Q2 		$6.91M Sell
60,810
-892
-1% -$95.3K 1.26% 13
2025
Q1 		$6.49M Sell
61,702
-3,545
-5% -$401K 1.35% 11
2024
Q4 		$6.99M Sell
65,247
-3,901
-6% -$441K 1.26% 14
2024
Q3 		$6.92M Sell
69,148
-1,632
-2% -$164K 1.21% 13
2024
Q2 		$5.96M Buy
+70,780
New +$5.63M 1.12% 20
2014
Q3 		– Sell
-25,079
Closed -$975K – 371
2014
Q2 		$975K Sell
25,079
-5,045
-17% -$205K 0.14% 186
2014
Q1 		$1.26M Sell
30,124
-10,757
-26% -$448K 0.18% 170
2013
Q4 		$1.34M Sell
40,881
-9,642
-19% -$314K 0.19% 157
2013
Q3 		$1.36M Sell
50,523
-4,463
-8% -$126K 0.21% 139
2013
Q2 		$1.28M Buy
+54,986
New +$989K 0.23% 121

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Essex Investment Management's LGND Position: Q1 2026 in Review

Essex Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 2.6% in Q1 2026, selling an estimated $309K and leaving 58,460 shares worth $11.7M. The position accounts for 1.85% of the portfolio, ranked #5.

Essex Investment Management first reported a position in LGND in Q2 2013 and has held it in 13 quarters since. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Essex Investment Management held 58,460 shares of Ligand Pharmaceuticals worth $11.7M as of Q1 2026.
  • Essex Investment Management sold 1,560 Ligand Pharmaceuticals shares in Q1 2026, an estimated $309K.
  • Ligand Pharmaceuticals made up 1.85% of Essex Investment Management's portfolio in Q1 2026, its #5 holding.
  • Essex Investment Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
  • 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Essex Investment Management's 13F filing for Q1 2026, filed 11 May 2026.